National Institute on Drug Abuse; Notice of Closed Meeting, 17096 [2022-06298]
Download as PDF
<![CDATA[
17096
Federal Register / Vol. 87, No. 58 / Friday, March 25, 2022 / Notices
OMB approval is requested for 3
years. There are no costs to respondents
other than their time. The total
estimated annualized burden hours are
785.
ESTIMATED ANNUALIZED BURDEN HOURS
Information Collection Questionnaire (Data Management System) (HWWTP, DOE).
Information Collection Questionnaire (Survey)
SBIR.
Grantee .........................
25
2
14
700
Grantee .........................
85
1
1
85
Total ...............................................................
.......................................
110
135
........................
785
[FR Doc. 2022–06346 Filed 3–24–22; 8:45 am]
BILLING CODE 4140–01–P
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: March 21, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
National Institutes of Health
[FR Doc. 2022–06298 Filed 3–24–22; 8:45 am]
BILLING CODE 4140–01–P
National Institute on Drug Abuse;
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
lotter on DSK11XQN23PROD with NOTICES1
Average time
per response
(in hours)
Type of
respondent
Jane M. Lambert,
Project Clearance Liaison, National Institute
of Environmental Health Sciences, National
Institutes of Health.
Number of
respondents
Number of
responses per
respondent
Form name
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; Purity
Specifications, Storage and Distribution of
Medications Development (8961).
Date: May 2, 2022.
Time: 12:00 p.m. to 1:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Trinh T. Tran, Ph.D.,
Scientific Review Officer, Office of
Extramural Policy and Review, Division of
Extramural Research, National Institute on
Drug Abuse, NIH, 301 North Stonestreet
Avenue, MSC 6021, Bethesda, MD 20892,
(301) 827–5843, trinh.tran@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
VerDate Sep<11>2014
16:50 Mar 24, 2022
Jkt 256001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Total annual
burden hour
Contact Person: Konrad Krzewski, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3G53, Rockville, MD
20852, 240–747–7526, konrad.krzewski@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: March 21, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–06297 Filed 3–24–22; 8:45 am]
National Institutes of Health
BILLING CODE 4140–01–P
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIH Support for
Conferences and Scientific Meetings (Parent
R13 Clinical Trial Not Allowed).
Date: April 27–29, 2022.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G53,
Rockville, MD 20892 (Virtual Meeting).
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
DEPARTMENT OF HOMELAND
SECURITY
Coast Guard
[Docket No. USCG–2022–0203]
Cooperative Research and
Development Agreement—Beyond
Visual Line of Sight (BVLOS)
Technology for Coast Guard (CG)
Unmanned Aircraft System (UAS)
Operations
Coast Guard, DHS.
Notice of intent; request for
comments.
AGENCY:
ACTION:
The Coast Guard announces
its intent to enter into a cooperative
research and development agreement
(CRADA) with companies to evaluate a
detect and avoid (DAA) system to
determine its potential use in a
maritime environment to enable the
Coast Guard to safely fly small UAS
(SUAS) beyond visual line of sight
(BVLOS). The Coast Guard will conduct
flight testing and evaluations of SUAS
DAA technology against CG mission
scenarios. From our previous
solicitations, the Coast Guard is
SUMMARY:
E:\FR\FM\25MRN1.SGM
25MRN1
]]>Agencies
[Federal Register Volume 87, Number 58 (Friday, March 25, 2022)]
[Notices]
[Page 17096]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-06298]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The contract proposals and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the contract proposals, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Purity Specifications, Storage and Distribution of
Medications Development (8961).
Date: May 2, 2022.
Time: 12:00 p.m. to 1:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Trinh T. Tran, Ph.D., Scientific Review Officer,
Office of Extramural Policy and Review, Division of Extramural
Research, National Institute on Drug Abuse, NIH, 301 North
Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 827-5843,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug
Abuse Scientist Development Award for Clinicians, Scientist
Development Awards, and Research Scientist Awards; 93.278, Drug
Abuse National Research Service Awards for Research Training;
93.279, Drug Abuse and Addiction Research Programs, National
Institutes of Health, HHS)
Dated: March 21, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-06298 Filed 3-24-22; 8:45 am]
BILLING CODE 4140-01-P
